Alexei brings 20+ years of Research & Development expertise in Obesity/Diabetes/NASH and associated morbidities acquired in Pharma and Biotech. A highly respected scientific thought leader, his most outstanding academic achievement in the industry environment was the discovery of Fibroblast Growth Factor 21 (FGF21) as a metabolic hormone, a major scientific advancement in the identification of a novel target class/therapeutic concept to combat various metabolic disorders. Alexei effectively led research efforts yielding several clinical candidates to treat Diabetes, Obesity and NASH at Lilly, Calibrium, and Novo Nordisk.
Bio
Alexei earned his PhD in Biochemistry from Moscow State University, Russia, in 1991. In 1992-1997 Alexei completed his postdoctoral training in Signal Transduction at the Max-Planck-Institute for Biochemistry, Martinsried, Germany. Alexei’s most notable achievement during this period was the discovery of a novel family of Signal-Regulatory Proteins (SIRPs). In 1998 Alexei joined Lilly Research Laboratories where he directed the General Metabolism Unit in Diabetes Research. For his work on FGF21 and other metabolic hormones Alexei was awarded the Eli Lilly Company President’s Award. In 2015 Alexei moved to Calibrium, LLC. Upon the successful acquisition of the company in 2016, Alexei has joined Novo Nordisk, Inc., where he continued his research on the endocrine FGFs with primary interests being within the translational aspects of expanding the boundaries of metabolic drug discovery.
Throughout his scientific career, Alexei has published over 100 manuscripts in high-profile scientific journals, served as an inventor on several registered patents, made multiple presentations, and organized various research conferences